CRIS Current Research Information System

LUATTI, SIMONA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.654
AS - Asia 2.124
EU - Europa 1.781
AF - Africa 131
Continente sconosciuto - Info sul continente non disponibili 109
SA - Sud America 94
OC - Oceania 5
Totale 6.898
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.618
VN - Vietnam 715
CN - Cina 534
SG - Singapore 506
GB - Regno Unito 438
SE - Svezia 292
DE - Germania 233
IT - Italia 230
FR - Francia 105
HK - Hong Kong 97
IN - India 97
UA - Ucraina 85
RU - Federazione Russa 82
NL - Olanda 80
BR - Brasile 65
IE - Irlanda 55
FI - Finlandia 36
TG - Togo 35
EE - Estonia 34
KR - Corea 34
ZA - Sudafrica 33
CH - Svizzera 30
JP - Giappone 30
JO - Giordania 28
BG - Bulgaria 26
CA - Canada 26
CI - Costa d'Avorio 25
BE - Belgio 18
PH - Filippine 16
SC - Seychelles 14
TH - Thailandia 12
AR - Argentina 10
BD - Bangladesh 10
NG - Nigeria 10
GR - Grecia 9
IR - Iran 9
CL - Cile 6
IQ - Iraq 6
AT - Austria 5
PL - Polonia 5
TR - Turchia 5
TW - Taiwan 5
EC - Ecuador 4
KE - Kenya 4
LT - Lituania 4
RO - Romania 4
AE - Emirati Arabi Uniti 3
AU - Australia 3
CO - Colombia 3
ID - Indonesia 3
IL - Israele 3
LB - Libano 3
MA - Marocco 3
MX - Messico 3
SA - Arabia Saudita 3
CZ - Repubblica Ceca 2
ES - Italia 2
HN - Honduras 2
MY - Malesia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PY - Paraguay 2
VE - Venezuela 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BY - Bielorussia 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EG - Egitto 1
GM - Gambi 1
GP - Guadalupe 1
GT - Guatemala 1
KH - Cambogia 1
LY - Libia 1
OM - Oman 1
PA - Panama 1
PE - Perù 1
PK - Pakistan 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TN - Tunisia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 6.790
Salva come PNG Salva come JPEG
Città #
Southend 378
Singapore 359
Fairfield 267
Ashburn 254
Chandler 247
Dong Ket 241
Woodbridge 140
Seattle 128
San Jose 127
Wilmington 127
Ann Arbor 119
Houston 119
Ho Chi Minh City 104
Cambridge 97
Hong Kong 90
Hefei 84
Beijing 81
Hanoi 77
Princeton 72
Boardman 58
Santa Clara 57
Dublin 55
Jacksonville 53
Nanjing 37
New York 36
Lomé 35
Westminster 35
Padova 34
Council Bluffs 32
Helsinki 32
Berlin 31
Lauterbourg 31
Turin 31
Seoul 30
Bologna 28
Dallas 28
Amman 27
Bern 27
Sofia 26
Abidjan 24
Florence 24
Bremen 23
Tokyo 23
Saint Petersburg 19
Brussels 18
Jinan 18
Milan 18
Munich 18
Redondo Beach 18
Frankfurt am Main 16
Los Angeles 16
Buffalo 14
Guangzhou 14
Shenyang 14
São Paulo 13
Hebei 12
Nanchang 12
Falkenstein 11
Hangzhou 11
Abeokuta 10
Castelfranco Emilia 10
Phoenix 10
San Diego 10
Da Nang 9
Falls Church 9
Brooklyn 8
Can Tho 8
Des Moines 8
Haiphong 8
Montreal 8
Orem 8
Redwood City 8
Shanghai 8
Tianjin 8
Zhengzhou 8
Changsha 7
Düsseldorf 7
Mahé 7
Mountain View 7
Mülheim 7
Chicago 6
Haikou 6
Hyderabad 6
Jiaxing 6
London 6
Nuremberg 6
Paris 6
Taizhou 6
Wuhan 6
Bengaluru 5
Chengdu 5
Ningbo 5
San Francisco 5
Taiyuan 5
Toronto 5
Verona 5
Xi'an 5
Atlanta 4
Boston 4
Long Xuyen 4
Totale 4.449
Salva come PNG Salva come JPEG
Nome #
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 347
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 279
Circulating calreticulin is increased in myelofibrosis: Correlation with interleukin-6 plasma levels, bone marrow fibrosis, and splenomegaly 265
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 258
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 257
BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia. 248
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia 243
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. 231
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 217
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 214
Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities 213
t(5;12)(q31;p13)/ETV6::ACSL6 and t(6;9)(p23;q34)/DEK::NUP214 concurrence in acute myeloid leukemia: an unusual association of two rare abnormalities 210
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP. 197
Crucial factors of the inflammatory microenvironment (IL-1β/ TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study 194
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. 185
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 185
Acute promyelocytic leukemia with amplification of PML-RARalpha rearrangement:clinical implications 184
Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis 183
Molecular and cytogenetic characterization of a new case of t(5;17)(q35;q21) variant acute promyelocytic leukemia 181
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 180
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 178
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 171
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 167
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis 165
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib 159
FGFR1 and KAT6A rearrangements in patients with hematological malignancies and chromosome 8p11 abnormalities: biological and clinical features 156
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy 156
Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience 143
The long-term durability of cytogenetic response in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up 140
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain 125
Results of high-dose imatinib mesylate in intermediate SOKAL risk chronic myeloid leukemia patients in early chronic phase: A phase II trial of the GIMEMA CML WP 123
Differences among young adults, adults and elderly chronic myeloid leukemia patients 120
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up 111
null 104
null 102
Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure 100
null 81
null 77
Erratum: Additional chromosomal abnormalities in Philadelphia-positive clone: Adverse prognostic influence on frontline imatinib therapy: A GIMEMA Working Party on CML analysis (Blood (2012) 120:4 (761-767)) 49
Totale 6.898
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.040
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.040
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022693 0 12 52 96 65 38 13 47 31 77 143 119
2022/2023953 110 159 57 119 62 75 22 52 148 20 89 40
2023/2024241 7 28 17 34 18 73 12 13 4 9 16 10
2024/2025797 31 107 57 55 117 43 73 27 1 120 28 138
2025/20261.714 160 148 167 115 192 84 151 57 387 141 45 67
2026/202781 30 51 0 0 0 0 0 0 0 0 0 0
Totale 6.898